RxDoctor Payments Data

Joanne Rossman, MD

Hematology & Oncology · Bessemer, ALNPI 1750501276

Payments from drug & device makers

$21,663in general payments, 2019–2025

Across 1,188 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Genentech USA, Inc.$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Johnson & Johnson$859
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$21,26898%
  • Education$3952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis91$1,651
E.r. Squibb & Sons, L.L.C.113$1,566
Genentech USA, Inc.83$1,316
AstraZeneca(2 entities)65$1,120
Pfizer69$1,027
Johnson & Johnson(2 entities)44$859
Bristol Myers Squibb44$839
Amgen48$743
Seagen Inc.41$738
Merck34$680
Takeda Pharmaceuticals U.S.A., Inc.28$605
Gilead(2 entities)30$559
Eisai Inc.29$549
Incyte Corporation23$538
AbbVie29$535
Ipsen Biopharmaceuticals, Inc24$532
Sanofi22$454
Daiichi Sankyo Inc.20$437
Lilly USA, LLC28$427
GSK22$400
Bayer23$399
Pharmacyclics LLC, An Abbvie Company23$366
CSL Behring9$313
Sobi, Inc12$278
Array Biopharma Inc12$273
Jazz Pharmaceuticals Inc.13$261
Blueprint Medicines Corporation10$219
Stemline Therapeutics Inc.7$190
Pharmaessentia USA Corporation6$173
Myriad Genetic Laboratories, Inc.9$164
Astellas Pharma US Inc8$160
Tersera Therapeutics LLC7$160
Acrotech Biopharma Inc.8$160
Servier Pharmaceuticals LLC7$152
Boehringer Ingelheim6$148
Deciphera Pharmaceuticals Inc.6$142
Genmab U.S., Inc.7$138
Sumitomo Pharma America, Inc.7$135
Taiho Oncology, Inc.8$124
Exelixis Inc.6$120
Karyopharm Therapeutics Inc.6$119
Regeneron Healthcare Solutions, Inc.7$118
Beigene USA, Inc.6$115
Dova Pharmaceuticals5$112
Puma Biotechnology, Inc.4$95
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$94
Tesaro, Inc.4$92
Beone Medicines USA, Inc.5$88
Pharmacosmos Therapeutics Inc.4$79
Rigel Pharmaceuticals, Inc.4$76
Mirati Therapeutics, Inc.4$76
EMD Serono, Inc.4$65
Adaptive Biotechnologies Corporation4$62
Springworks Therapeutics, Inc.3$62
EUSA Pharma (US) LLC3$60
Shield Therapeutics Inc3$58
Verastem, Inc.4$57
Helsinn Therapeutics (U.S.), Inc.3$54
ADC Therapeutics America, Inc.3$51
Sanofi-aventis U.S. LLC2$39

How this compares

$21,663 in reported general payments places this provider in the 60th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$2,442,532
Medicare patients
328
Services billed
151,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-50130$1,066,329
PanzygaImmun Glob G(Igg)-Ifas/Glycine21$295,342
BrukinsaZanubrutinib15$229,556
TasignaNilotinib Hcl20$227,269
SprycelDasatinib13$222,020
GammakedImmune Globul G/Gly/Iga Avg 4615$196,065
Gamunex-CImmune Globul G/Gly/Iga Avg 4639$194,487
VenclextaVenetoclax22$159,053
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5031$125,579
Lenalidomide12$107,714
XareltoRivaroxaban82$74,957
EliquisApixaban100$66,022
RelistorMethylnaltrexone Bromide14$31,063
OzempicSemaglutide26$23,979
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen406$11,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Eliquis$1,027$361,364121 claims
Beigene USA, Inc.Brukinsa$115$229,55615 claims
NovartisTasigna$1,651$227,26920 claims
E.r. Squibb & Sons, L.L.C.Sprycel$1,566$222,02013 claims
AbbVieVenclexta$535$159,05322 claims
CSL BehringPrivigen$313$125,57931 claims
Johnson & JohnsonXarelto$859$74,95782 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$94$31,06314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Bessemer

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →